Haeng Gyu Lee

JIPYONG - South Korea

Partner

Seoul

+82 2 6200 1744

Highly regarded

Korean
English


Bar admissions:

New York
South Korea

Jurisdictions:

South Korea

Practice areas:

Capital markets
M&A


Mr. Haeng Gyu Lee is a member of the Finance Practice Group and the head of Capital Markets Team at Jipyong.  Mr. Lee has been involved in major complex transactions related to capital markets including, without limitation, IPO, dual listing, GDR offering, de-listing. A recognized expert in the capital markets field, Mr. Lee advised on 8 IPOs, the largest number of IPOs advised by a Korean attorney in 2018.

As reflected in his significant track record, Mr. Lee is well-known for advising various companies which were first in their respective country of incorporation to be listed on the KRX, such as New Pride Corporation (US), Kolao Holdings (Laos), Fast Future Brands (Australia) and LS Cable & System Asia (Vietnam).  In this regard, Mr. Lee is currently representing Nanogen, Vietnam’s largest biosimilars company and Prestige Bio Pharma, a Singaporean biosimilars company on their listings on the KRX. Mr. Lee currently serves as a legal advisor for the KRX and KRX’s task force team to solicit excellent Asian companies to list on the KRX and also as a member of the Corporate Evaluation Committee under the Stock Market Division of the Korea Exchange.

Capital Markets Team is expected to excel this year under Mr. Lee’s leadership.  Key clients of Mr. Lee include major corporates such as Korea Investment & Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., Samsung Securities Co., Ltd., NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd. and KB Securities Co., Ltd.

  • Advised Korea Investment & Securities on the IPOs of Pum-tech Korea, Settle Bank, Xi S&D, SP Systems, Suprema ID
  • Advised Mirae Asset Daewoo Securities on the IPOs of KNJ, Lao People, Wooyang, ThiRa-Utech
  • Advised Olipass on the IPO
  • Advised Kakao Games on the IPO;
  • Advised Icure on its IPO;
  • Advised Korea Investment & Securities on the IPOs of S-Fuelcell and Bifido;
  • Advised Mirae Asset Daewoo Securities on the IPOs of SV Investment and Ajuib Investment; and
  • Advised Kiwoom Securities on the IPOs of Tnrbiofab and Cytogen.

  • Capital markets: Debt
  • Capital markets: Equity
  • Investment funds
  • M&A
  • Private equity

  • Banking
  • Financial services
  • Healthcare
  • Investment management
  • Pharma and life sciences

  • Korea (1999)
  • New York (2007)

  • Korean and Seoul Bar Associations
  • New York Bar Associations

  • Columbia Law School (LL.M., 2007)
  • Seoul National University (LL.B., 1996)